344
Views
0
CrossRef citations to date
0
Altmetric
Case Report

An adult case of human parvovirus B19 infection developed ACPA-positive rheumatoid arthritis

, , , , , , , , & show all
Pages 1-4 | Received 09 Mar 2018, Accepted 05 Jun 2018, Published online: 10 Sep 2018
 

Abstract

We report a case of rheumatoid arthritis (RA) developing after parvovirus B19 infection. A 30-year-old Japanese woman, who had no significant medical history admitted for tender erythema in the bilateral upper limbs with progressive polyarthralgia. Serological test showed elevation of serum IgM antibodies for parvovirus B19. Serum anti-cyclic citrullinated peptide antibody (ACPA) and RF were increased at 95.8 U/mL (normal, ≤4.4 U/mL) and 22 IU/mL (normal, ≤15 IU/mL). Radiographs of the hand showed no narrowing of the joint space or bone erosion. Although the erythema of both upper limbs disappeared, polyarthritis persisted. Because C-reactive protein (CRP) and ACPA and RF showed an upward trend, RA was diagnosed together with clinical symptoms. Oral methotrexate was begun at 8 mg/week. Joint pain was alleviated after 1 month, synovitis disappeared after 2 months, and CRP and MMP3 values were negative after 3 months. This case seems to be very rare case which reported a direct relationship between human parvovirus B19 infection and ACPA-positive RA.

Conflict of interest

None.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.